A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
<p>Abstract</p> <p>Background</p> <p>Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound neutropenia following induction and/or consolidation chemotherapy and this may result in serious, potentially...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMC
2008-07-01
|
| 叢編: | BMC Cancer |
| 在線閱讀: | http://www.biomedcentral.com/1471-2407/8/195 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|